Carbohydrate antigen 15-3 (CA15-3) and carcino-embryonic antigen (CEA) are blood-based biomarkers that are currently used for BC screening and treatment response monitoring; however, their sensitivity and specificity remain poor8. This evidence concerns the gene CEACAM5 and breast cancer.